Back

Lithium therapy and delayed progression of Alzheimer's disease and related dementias in patients with bipolar disorder and mild neurocognitive disorders

Weckstein, A. R.; Carr, S.; Wang, P.; Krüger, N.; Danaei, G.; Schneeweiss, S.; Desai, R. J.

2026-01-13 epidemiology
10.64898/2026.01.12.26343472 medRxiv
Show abstract

Recent mechanistic evidence identifies lithium deficiency as a driver of Alzheimers disease and related dementias (ADRD) pathogenesis. To evaluate this hypothesis in a population-based setting, we emulated a target trial comparing ADRD progression after initiation of lithium versus antiepileptic mood stabilizers among adults [≥]55 years with bipolar disorder and mild neurocognitive disorder, using US Medicare claims with replication in two commercial databases. Lithium initiation was associated with a lower 5-year risk of progression to advanced ADRD (risk ratio 0.87; 95% CI 0.78-0.99) and long-term care stay with ADRD (0.75; 0.56-0.97). Lower risks were most pronounced in patients with later stages of mild cognitive impairment. Results were consistent across sensitivity analyses and replications. Validations using linked cognitive assessments from standardized instruments strengthened confidence in findings. While results may be susceptible to residual bias, this study supports investigating lithiums potential to delay ADRD progression with randomized trials of optimized lithium formulations.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.